In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Neurology-focused nVNS device company electroCore nets $83.4mm in IPO

Executive Summary

Noninvasive vagus nerve stimulation (nVNS) device company electroCore Inc. (focused on neurology and rheumatology) netted $83.4mm in its initial public offering of 5.98mm shares (including the overallotment) at $15, the midpoint of its proposed range. The company originally planned to sell 4.33mm shares.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Rehabilitation Equipment and Devices
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies